How many drugs treat hypercholesterolemia?

Drug Landscape tracks 10 marketed treatments for hypercholesterolemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hypercholesterolemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

hypercholesterolemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

hypercholesterolemia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating hypercholesterolemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Lerochol	LERODALCIBEP	Lib Therapeutics, Inc.			2025-01-01
Repatha	EVOLOCUMAB	Repatha	PCSK9 Inhibitor [EPC]	PCSK9	2015-01-01
Praluent	ALIROCUMAB	Sanofi	PCSK9 Inhibitor [EPC]	Proprotein convertase subtilisin/kexin type 9	2015-01-01
Livalo	PITAVASTATIN	Kowa Co	HMG-CoA Reductase Inhibitor	3-hydroxy-3-methylglutaryl-coenzyme A reductase	2009-01-01
Trilipix	CHOLINE FENOFIBRATE	AbbVie	Peroxisome Proliferator Receptor alpha Agonist	Fatty acid-binding protein, intestinal	2008-01-01
Crestor	rosuvastatin	AstraZeneca	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Zetia	EZETIMIBE	Merck & Co.	HMG-CoA Reductase Inhibitor [EPC]	Niemann-Pick C1-like protein 1	2002-01-01
Welchol	COLESEVELAM	Cosette	Bile Acid Sequestrant		2000-01-01
Baycol	CERIVASTATIN	Bayer	cerivastatin	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1997-01-01
Lipitor	atorvastatin	Pfizer Inc.	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Merck & Co. · 3 drugs in hypercholesterolemia
· 3 drugs in hypercholesterolemia
Pfizer · 2 drugs in hypercholesterolemia
Bayer · 1 drug in hypercholesterolemia
Bristol Myers · 1 drug in hypercholesterolemia
Cedars-Sinai Medical Center · 1 drug in hypercholesterolemia
Cosette · 1 drug in hypercholesterolemia
Daiichi Sankyo · 1 drug in hypercholesterolemia
Kowa Co · 1 drug in hypercholesterolemia
Kowa Research Institute, Inc. · 1 drug in hypercholesterolemia
Lib Therapeutics, Inc. · 1 drug in hypercholesterolemia
MEDPOINTE PHARM HLC · 1 drug in hypercholesterolemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in hypercholesterolemia:

Cite this brief

Drug Landscape (2026). hypercholesterolemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hypercholesterolemia. Accessed 2026-06-10.

hypercholesterolemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing